1. Long-Term Follow-Up of Allogeneic Hematopoietic Stem Cell Transplantation for Solid Cancer 
Brigitta Omazic, Mats Remberger, Lisbeth Barkholt, Gunnar Söderdahl, Zuzana Potácová, Peter Wersäll, Bo-Göran Ericzon, Jonas Mattsson, Olle Ringdén 
Biology of Blood and Marrow Transplantation 
Volume 22, Issue 4, Pages (April 2016)
DOI: /j.bbmt
Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
(A) Time to and cumulative incidence of acute GVHD of grades II to IV. (B) Time to and cumulative incidence of chronic GVHD. (C) The cumulative incidence of TRM.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
(A) Probability of survival in patients who underwent HSCT for solid cancer. (B) Time to and cumulative incidence of death from progressive cancer. (C) Proportion of surviving patients after HSCT for solid cancers with 0, 1, 2, or 3 risk factors including nonmyeloablative conditioning, absence of chronic GVHD, acute GVHD of grades II to IV, and HLA-A, -B, and -DR matched transplants.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions